Yasumasa Ohyagi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yasumasa Ohyagi has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Jun-Ichi Kira
Department of Neurology, Brain and Nerve Center Fukuoka Central Hospital Fukuoka Japan
5 shared publications - Masayuki Ochi
Department of Neurology and Geriatric Medicine, Ehime University School of Medicine, Toon, Ehime, Japan
5 shared publications - Michiya Igase
Department of Integrated Medicine and Informatics Ehime University Graduate School of Medicine Toon Japan
4 shared publications - Yoko Okada
Department of Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, 791-0295, Japan
4 shared publications - Ryo Yamasaki
Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
3 shared publications - Yasuharu Tabara
Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan
3 shared publications
Latest Publications
- Open Access
- 16 March 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 34 (6) , 108287
Morphologic variation of the circle of Willis is associated with cognitive impairment in a general population: The J-SHIPP study
- 16 March 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 34 (6) , 108287
Open AccessMorphologic variation of the circle of Willis is associated with cognitive impairment in a general population: The J-SHIPP study
- Open Access
- 13 September 2024
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 15, 330
A case of immunocompetent intracranial cryptococcoma in which intraoperative rapid pathological diagnosis and polymerase chain reaction led to early treatment: What to know to avoid misdiagnosis as brain tumor
Background: Cryptococcal infections of the central nervous system are infrequent in immunocompetent hosts and usually present as meningitis. However, a fungal mass called a cryptococcoma may form, requiring caution in therapeutic intervention. Here, we report a rare case in which treatment of intraventricular cryptococcoma in an immunocompetent patient was facilitated by rapid pathological diagnosis. Case Description: A 58-year-old previously healthy man was admitted to our hospital with fever, headache, and gradually worsening hearing loss over 1 month. Cerebrospinal fluid analysis showed moderately elevated levels of protein and lymphocytic cells and decreased glucose. In addition, β2-microglobulin was highly elevated. Magnetic resonance imaging showed homogeneously enhanced lesions in lateral ventricles of the left and right hemispheres and the subarachnoid space, and 18F-fluorodeoxyglucose positron emission tomography revealed abnormal uptake corresponding to the lesion. A surgical excision was performed to achieve a definitive diagnosis. Intraoperative rapid pathology, including immunohistochemistry (IHC), yielded negative results for malignant tumor, suggesting the possibility of inflammatory granuloma. Additional targeted pathological diagnosis was immediately performed. Paraffin-embedded histopathological examination showed fibrocaseous granuloma and numerous fungal spores. Cryptococcus neoformans within the granuloma were suggested by Fontana–Masson and Grocott staining and confirmed by polymerase chain reaction (PCR), leading to a diagnosis of cryptococcoma. Antifungal agents were started 3 days postoperatively. The patient has since been doing well, with no recurrence. Conclusion: This pathology can be difficult to distinguish from a brain tumor, so early pathological diagnosis, including rapid pathology with IHC and PCR, may be crucial.
- 13 September 2024
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 15, 330
Open AccessA case of immunocompetent intracranial cryptococcoma in which intraoperative rapid pathological diagnosis and polymerase chain reaction led to early treatment: What to know to avoid misdiagnosis as brain tumor
Background: Cryptococcal infections of the central nervous system are infrequent in immunocompetent hosts and usually present as meningitis. However, a fungal mass called a cryptococcoma may form, requiring caution in therapeutic intervention. Here, we report a rare case in which treatment of intraventricular cryptococcoma in an immunocompetent patient was facilitated by rapid pathological diagnosis. Case Description: A 58-year-old previously healthy man was admitted to our hospital with fever, headache, and gradually worsening hearing loss over 1 month. Cerebrospinal fluid analysis showed moderately elevated levels of protein and lymphocytic cells and decreased glucose. In addition, β2-microglobulin was highly elevated. Magnetic resonance imaging showed homogeneously enhanced lesions in lateral ventricles of the left and right hemispheres and the subarachnoid space, and 18F-fluorodeoxyglucose positron emission tomography revealed abnormal uptake corresponding to the lesion. A surgical excision was performed to achieve a definitive diagnosis. Intraoperative rapid pathology, including immunohistochemistry (IHC), yielded negative results for malignant tumor, suggesting the possibility of inflammatory granuloma. Additional targeted pathological diagnosis was immediately performed. Paraffin-embedded histopathological examination showed fibrocaseous granuloma and numerous fungal spores. Cryptococcus neoformans within the granuloma were suggested by Fontana–Masson and Grocott staining and confirmed by polymerase chain reaction (PCR), leading to a diagnosis of cryptococcoma. Antifungal agents were started 3 days postoperatively. The patient has since been doing well, with no recurrence. Conclusion: This pathology can be difficult to distinguish from a brain tumor, so early pathological diagnosis, including rapid pathology with IHC and PCR, may be crucial.
- 29 March 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (5) , 793-799
Bioimpedance phase angle is independently associated with myosteatosis: The Shizuoka study
- 29 March 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (5) , 793-799
Bioimpedance phase angle is independently associated with myosteatosis: The Shizuoka study
- Open Access
- 1 January 2021
- Published by Japan Academy of Neurosonology in Neurosonology
- Vol. 34 (3) , 142-147
Reliability of cerebral vasoreactivity assessment from the submandibular window
Background and Purpose: Transcranial Doppler (TCD) is a noninvasive and effective technique for the measurement of cerebrovascular function. Measurement of breath holding index (BHI) in the middle cerebral artery is commonly performed to determine cerebrovascular reactivity. Nevertheless, a notable drawback of TCD is the absence of a transtemporal acoustic bone window. The submandibular window offers an alternative way to measure BHI. Here, we studied the diagnostic accuracy of cerebrovascular reactivity (CVR) in the internal carotid artery (ICA) as measured from the submandibular window. Methods: Twenty-five volunteers (13 male, 12 female) with sufficient temporal acoustic bone windows were assessed. BHI was measured by mean blood velocities before and after breath holding. The correlation of BHI measured in ICA (BHIi) and ipsilateral middle cerebral artery (BHIm) was assessed. Results: The mean age of the participants was 39.9 ± 13.7 years. The mean BHIm and BHIi values were 0.93 ± 0.29 and 0.92 ± 0.32, respectively. Spearman’s correlation coefficient between BHIm and BHIi was 0.665 (p = 0.0003). The cutoff point of the BHIi value for CVR impairment determined by BHIm was 0.71 (sensitivity 80.0%, specificity 80.0%). Conclusion: Measuring BHI from the submandibular window may be a useful procedure in the case of temporal bone window insufficiency.
- 1 January 2021
- Published by Japan Academy of Neurosonology in Neurosonology
- Vol. 34 (3) , 142-147
Open AccessReliability of cerebral vasoreactivity assessment from the submandibular window
Background and Purpose: Transcranial Doppler (TCD) is a noninvasive and effective technique for the measurement of cerebrovascular function. Measurement of breath holding index (BHI) in the middle cerebral artery is commonly performed to determine cerebrovascular reactivity. Nevertheless, a notable drawback of TCD is the absence of a transtemporal acoustic bone window. The submandibular window offers an alternative way to measure BHI. Here, we studied the diagnostic accuracy of cerebrovascular reactivity (CVR) in the internal carotid artery (ICA) as measured from the submandibular window. Methods: Twenty-five volunteers (13 male, 12 female) with sufficient temporal acoustic bone windows were assessed. BHI was measured by mean blood velocities before and after breath holding. The correlation of BHI measured in ICA (BHIi) and ipsilateral middle cerebral artery (BHIm) was assessed. Results: The mean age of the participants was 39.9 ± 13.7 years. The mean BHIm and BHIi values were 0.93 ± 0.29 and 0.92 ± 0.32, respectively. Spearman’s correlation coefficient between BHIm and BHIi was 0.665 (p = 0.0003). The cutoff point of the BHIi value for CVR impairment determined by BHIm was 0.71 (sensitivity 80.0%, specificity 80.0%). Conclusion: Measuring BHI from the submandibular window may be a useful procedure in the case of temporal bone window insufficiency.
- Open Access
- 1 April 2020
- Published by Elsevier in Neurobiology of Disease
- Vol. 137, 104739
Insulin deficiency promotes formation of toxic amyloid-β42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer's disease model
- 1 April 2020
- Published by Elsevier in Neurobiology of Disease
- Vol. 137, 104739
Open AccessInsulin deficiency promotes formation of toxic amyloid-β42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer's disease model
- Open Access
- 30 January 2020
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 8 (3) , 146-154
Insulin signaling as a therapeutic target in Alzheimer’s disease: Efficacy of apomorphine
Alzheimer's disease has recently been characterized as “diabetes of the brain” or “type 3 diabetes.” Although recent clinical trials targeting amyloid β‐protein have been unsuccessful, glucose‐insulin metabolism in the brain may provide an alternative therapeutic target. In this review, we focus on three related topics: (a) how peripheral and brain insulin resistance interact with each other; (b) brain insulin resistance as a promising therapeutic target for Alzheimer's disease and anti‐diabetic drugs as potentially effective drugs; and (c) apomorphine as a novel drug that improves neuronal insulin signaling. Although apomorphine is a dopamine receptor agonist, studies in our laboratory revealed a novel effect, promoting intracellular amyloid β degradation and improving memory function in an Alzheimer's disease mouse model. Recently, we demonstrated that apomorphine treatment improved neuronal insulin resistance and activated insulin‐degrading enzyme, a major amyloid β‐degrading enzyme. In addition, we confirmed the efficacy of apomorphine for some Alzheimer's disease patients. In this context, combined treatment involving anti‐diabetic drugs and apomorphine may provide an effective therapeutic approach for Alzheimer's disease.
- 30 January 2020
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 8 (3) , 146-154
Open AccessInsulin signaling as a therapeutic target in Alzheimer’s disease: Efficacy of apomorphine
Alzheimer's disease has recently been characterized as “diabetes of the brain” or “type 3 diabetes.” Although recent clinical trials targeting amyloid β‐protein have been unsuccessful, glucose‐insulin metabolism in the brain may provide an alternative therapeutic target. In this review, we focus on three related topics: (a) how peripheral and brain insulin resistance interact with each other; (b) brain insulin resistance as a promising therapeutic target for Alzheimer's disease and anti‐diabetic drugs as potentially effective drugs; and (c) apomorphine as a novel drug that improves neuronal insulin signaling. Although apomorphine is a dopamine receptor agonist, studies in our laboratory revealed a novel effect, promoting intracellular amyloid β degradation and improving memory function in an Alzheimer's disease mouse model. Recently, we demonstrated that apomorphine treatment improved neuronal insulin resistance and activated insulin‐degrading enzyme, a major amyloid β‐degrading enzyme. In addition, we confirmed the efficacy of apomorphine for some Alzheimer's disease patients. In this context, combined treatment involving anti‐diabetic drugs and apomorphine may provide an effective therapeutic approach for Alzheimer's disease.
- 9 January 2020
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 8 (2) , 96-98
Sporadic Japanese case of adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia caused by a de novo p.Phe849del mutation in CSF1R
- 9 January 2020
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 8 (2) , 96-98
Sporadic Japanese case of adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia caused by a de novo p.Phe849del mutation in CSF1R
- 7 May 2019
- Published by Springer Nature
- Vol. 1128, 227-248
Therapeutic Strategies for Alzheimer’s Disease in the View of Diabetes Mellitus
Recently, Alzheimer’s disease (AD) is understood as “diabetes of the brain” or “type 3 diabetes.” Recent clinical trials of anti-amyloid β-protein (Aβ) therapies have not proved to be successful. Thus, glucose-insulin metabolism in the brain is thought to be an alternative therapeutic target. Various types of antidiabetic drugs such as insulin, thiazolidinediones, dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, biguanides, and others have been reported to be effective on cognitive impairment in animal models and patients with DM or AD. Here, recent reports are reviewed. While we identified apomorphine (APO) as a novel drug that promoted intracellular Aβ degradation and improved memory function in an AD mouse model, more recently, we have revealed that APO treatment improves neuronal insulin resistance and activates insulin-degrading enzyme (IDE), a major Aβ-degrading enzyme. In this context, recovery of impaired insulin signaling in AD neurons may be a promising therapeutic strategy for AD dementia.
- 7 May 2019
- Published by Springer Nature
- Vol. 1128, 227-248
Therapeutic Strategies for Alzheimer’s Disease in the View of Diabetes Mellitus
Recently, Alzheimer’s disease (AD) is understood as “diabetes of the brain” or “type 3 diabetes.” Recent clinical trials of anti-amyloid β-protein (Aβ) therapies have not proved to be successful. Thus, glucose-insulin metabolism in the brain is thought to be an alternative therapeutic target. Various types of antidiabetic drugs such as insulin, thiazolidinediones, dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, biguanides, and others have been reported to be effective on cognitive impairment in animal models and patients with DM or AD. Here, recent reports are reviewed. While we identified apomorphine (APO) as a novel drug that promoted intracellular Aβ degradation and improved memory function in an AD mouse model, more recently, we have revealed that APO treatment improves neuronal insulin resistance and activates insulin-degrading enzyme (IDE), a major Aβ-degrading enzyme. In this context, recovery of impaired insulin signaling in AD neurons may be a promising therapeutic strategy for AD dementia.
- 25 May 2017
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 58 (4) , 1151-1161
Apomorphine Therapy for Neuronal Insulin Resistance in a Mouse Model of Alzheimer’s Disease
Apomorphine (APO) promotes intraneuronal amyloid-β (Aβ) degradation and improves memory function in an Alzheimer’s disease (AD) model, 3xTg-AD mice. Since insulin resistance is increased in AD neurons, we investigated the effects of APO on brain insulin resistance in 3xTg-AD mice at early and late stages. After 1-month subcutaneous injection of Apokyn ® to 3xTg-AD mice at 6 or 12 months of age, memory function was significantly improved in both age groups. Protein levels of insulin-degrading enzyme (IDE), which is linked to insulin signaling and degrades Aβ, significantly increased in the 3xTg-AD mice brain compared with non-transgenic mice, and were further increased by APO. Protein levels of two types of serine-phosphorylated insulin receptor substrate-1 (IRS-1), pS 616 and pS 636/639 , significantly decreased following APO treatment in the 13-month-old 3xTg-AD mice brain, suggesting improved brain insulin resistance. Immunostaining of the IDE, pS 616 and pS 636/639 IRS-1 demonstrated similar changes due to APO treatment. Thus, brain insulin resistance is considered an important therapeutic target in AD, and APO may provide improved neuronal insulin resistance.
- 25 May 2017
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 58 (4) , 1151-1161
Apomorphine Therapy for Neuronal Insulin Resistance in a Mouse Model of Alzheimer’s Disease
Apomorphine (APO) promotes intraneuronal amyloid-β (Aβ) degradation and improves memory function in an Alzheimer’s disease (AD) model, 3xTg-AD mice. Since insulin resistance is increased in AD neurons, we investigated the effects of APO on brain insulin resistance in 3xTg-AD mice at early and late stages. After 1-month subcutaneous injection of Apokyn ® to 3xTg-AD mice at 6 or 12 months of age, memory function was significantly improved in both age groups. Protein levels of insulin-degrading enzyme (IDE), which is linked to insulin signaling and degrades Aβ, significantly increased in the 3xTg-AD mice brain compared with non-transgenic mice, and were further increased by APO. Protein levels of two types of serine-phosphorylated insulin receptor substrate-1 (IRS-1), pS 616 and pS 636/639 , significantly decreased following APO treatment in the 13-month-old 3xTg-AD mice brain, suggesting improved brain insulin resistance. Immunostaining of the IDE, pS 616 and pS 636/639 IRS-1 demonstrated similar changes due to APO treatment. Thus, brain insulin resistance is considered an important therapeutic target in AD, and APO may provide improved neuronal insulin resistance.
- Open Access
- 13 April 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 46419
Office-based simple frailty score and central blood pressure predict mild cognitive impairment in an apparently healthy Japanese population: J-SHIPP study
Frailty is associated with cognitive impairment and can be used to identify people at high risk for dementia. We developed a simple frailty (SF) score using a combination of low hand grip strength (<32.5 kg in men, <19.5 kg in women), and short one-leg standing time (<20 seconds). These can be easily measured in the clinician’s office when seeing patients. We investigated the possible association between SF score and mild cognitive impairment (MCI) in a cross-sectional study with 838 independent middle-aged to elderly participants (319 men, mean age 65.1years). In total, 118 participants were diagnosed with MCI. A SF score of 2 was significantly associated with the presence of MCI (odds ratio 4.6, 95% confidence interval: 1.9–6.9, p = 0.0001) even after adjustment for age and sex. Stepwise regression analyses showed that a SF score of 2 was associated with the presence of MCI, independently of central pulse pressure and silent cerebral infarcts. These findings indicate that the SF score is a useful frailty parameter to predict MCI in an apparently independent population.
- 13 April 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 46419
Open AccessOffice-based simple frailty score and central blood pressure predict mild cognitive impairment in an apparently healthy Japanese population: J-SHIPP study
Frailty is associated with cognitive impairment and can be used to identify people at high risk for dementia. We developed a simple frailty (SF) score using a combination of low hand grip strength (<32.5 kg in men, <19.5 kg in women), and short one-leg standing time (<20 seconds). These can be easily measured in the clinician’s office when seeing patients. We investigated the possible association between SF score and mild cognitive impairment (MCI) in a cross-sectional study with 838 independent middle-aged to elderly participants (319 men, mean age 65.1years). In total, 118 participants were diagnosed with MCI. A SF score of 2 was significantly associated with the presence of MCI (odds ratio 4.6, 95% confidence interval: 1.9–6.9, p = 0.0001) even after adjustment for age and sex. Stepwise regression analyses showed that a SF score of 2 was associated with the presence of MCI, independently of central pulse pressure and silent cerebral infarcts. These findings indicate that the SF score is a useful frailty parameter to predict MCI in an apparently independent population.